Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC).
To view Multimedia News Release, go to http://www.multivu.com/mnr/50924-dendreon-provenge-cellular-immunotherapy
"HOT PROMO DARI P0KERV1TA untuk para member kami :
* B0nus Referral 20% Seumur Hidup
* Bonus Hariaan Hingga 3juta
* Bonus Bulanan Hadiah Spesial untuk member yang bermain selama 1 bulan penuh
* Bonus Turn0ver 0,5%
* NO ROBOT & ADMIN
* 100% Fair Play Member Vs Member
* Proses Withdraw & Deposit Tercepat
* Customer Service yang baik dan ramah
Contact Us Person :
? LIVECHAT POKERV1TA
? WA: 082312256064
? BBM : D88B0154"
